What Is a Priority Review Voucher? The $100M Biotech Asset

Problem

A small-cap biotech you’ve never heard of announces it sold a “priority review voucher” for $150 million. The stock jumps 40% in a day. You have no idea what a priority review voucher is, why someone would pay $150 million for one, or whether you should buy, hold, or sell. Here’s what I wish someone had told me about PRVs before I traded my first rare-disease biotech.

Solution

A priority review voucher (PRV) is a transferable FDA coupon that converts a standard 10-month drug review into a 6-month priority review. The holder can use it on any drug application or sell it to another company. Big pharma pays $80 million to $180 million for one because four extra months of exclusivity on a $1B+ revenue drug is worth far more than the purchase price.

Step-by-step

Step 1: Understand what a PRV actually does

The FDA normally reviews a New Drug Application in 10 months (standard review) or 6 months (priority review, reserved for drugs that offer major advances). A PRV lets any application, even one that would otherwise get standard review, jump to the 6-month track. The buyer pays a priority review user fee on top of the purchase price (~$2.5 million in fiscal 2025, per the Federal Register fee notice).

That four-month acceleration sounds small. It isn’t. For a drug generating $5 billion a year, four extra months of sales before generic entry can be worth $1.5 billion. That’s why big pharma pays $100 million-plus for a coupon.

Step 2: Learn the four PRV programs

Congress created four separate PRV programs, each with its own eligibility rules:

Tropical Disease PRV (2007): the original program, created to incentivize drugs for neglected tropical diseases like Chagas, leishmaniasis, and cholera. The only program drafted without a sunset clause.
Rare Pediatric Disease PRV (2012): the most active program, awarded for drugs treating rare diseases that primarily affect children. Reauthorized in February 2026, but the FDA may not award new PRVs under this program after September 30, 2029 (see the FDA’s PRV program page).
Medical Countermeasures PRV (2016): for drugs targeting chemical, biological, radiological, or nuclear threats (e.g., smallpox, anthrax).
Rare Disease PRV (deemed to be a License provision): biologics approved for rare diseases under certain BLA pathways may qualify.

The Rare Pediatric Disease program is where most of the action is. That’s also the program with a sunset clock, which is why recent sale prices have spiked: buyers are paying a premium while the supply is still flowing.

Step 3: Know the economics: real sale prices

PRVs have sold for anywhere from $67 million to $180 million. Recent data from a BioSpace analysis of all 80 PRVs awarded shows the market tightened dramatically in 2024-2026 as the pediatric program approached reauthorization:

Rocket Pharmaceuticals (RCKT) sold its Rare Pediatric Disease PRV for $180 million in April 2026, awarded after FDA approval of Kresladi (gene therapy for severe leukocyte adhesion deficiency-I). Non-dilutive capital that extended their cash runway into Q2 2028. (Rocket press release)
Bavarian Nordic sold a PRV for $160 million in 2025 after approval of its chikungunya vaccine.
Ultragenyx sold a Rare Pediatric PRV for $130 million in 2017 after Mepsevii (MPS VII) approval.
Historical low: Novartis paid $21.2 million for a Pharming tropical-disease PRV in 2023, an outlier in a thin market.

The median sale price since 2017 is roughly $100 million. As the pediatric program sunsets, expect prices to stay at the high end.

Step 4: Understand the trading catalyst

The stock moves twice:

On PRV award confirmation, typically within ~30 days of drug approval, when the FDA formally grants the voucher. The stock pops on the optionality of a future sale.
On sale announcement, when the company discloses the buyer and price. This is the bigger move, because the cash hits the balance sheet.

For a $200 million market-cap biotech, a $150 million PRV sale is cash equal to 75% of the entire company’s value. That kind of non-dilutive capital can fund two more years of clinical trials without a secondary offering. The stock rerates on the news.

The mistake most retail investors make is buying after the sale announcement, when the move has already happened. The edge is in identifying PRV-eligible approvals before the market prices in the voucher. We explain the broader catalyst-trading framework in our how to trade FDA catalysts guide.

Step 5: Identify PRV-eligible approvals before the market does

Not every rare-disease approval earns a PRV. The drug must have received a Rare Pediatric Disease designation before approval, and the disease must meet the FDA’s prevalence and seriousness criteria. The practical workflow:

Watch the FDA’s rare pediatric disease designation list for drugs that received designation years ago and are now approaching PDUFA dates.
Cross-reference with the PDUFA calendar for rare-disease catalysts.
Check whether the company has publicly discussed PRV eligibility in its investor materials.

Real example: Ultragenyx (RARE) has a PDUFA date of September 19, 2026 for UX111, an AAV gene therapy for Sanfilippo syndrome type A (MPS IIIA), a rare pediatric disease. If approved, UX111 could be PRV-eligible. We analyzed that catalyst in our Ultragenyx UX111 Sanfilippo analysis. The PRV optionality is part of the bull case on the stock.

Step 6: Price in the sunset risk

The Rare Pediatric Disease PRV program is on a clock. The FDA may not award new PRVs under this program after September 30, 2029. Congress has reauthorized the program multiple times with reforms, and the February 2026 reauthorization extended the window, but investors should assume the program will eventually sunset.

What that means for trading: PRVs awarded before the sunset will remain transferable and usable even after the program closes. So companies with rare pediatric drugs currently in late-stage trials have a shrinking window to earn a voucher. The scarcity is already pushing sale prices higher. Once the program sunsets, the supply of new PRVs drops to zero and the tropical-disease program becomes the only ongoing source.

Critics have argued for years that PRVs let big pharma skip the line for non-rare-disease drugs. The FDA has called for eliminating the program. Congress has reauthorized it with restrictions each time. Treat the program’s existence as a political fact, not a permanent one. For more on the regulatory environment, see our primers on what a CRL is and what an FDA AdCom is.

Common mistakes

Buying the stock after the PRV sale is announced. The 30-50% move happens on the announcement. If you’re reading the headline, you’re late. The edge is in identifying PRV-eligible approvals before award.
Assuming every rare-disease approval earns a PRV. The drug needs a Rare Pediatric Disease designation before approval. Many rare-disease drugs don’t qualify. Check the designation list, not the disease name.
Ignoring the sunset risk. The pediatric program ends in 2029. A company whose drug won’t reach approval until 2030 may earn nothing. Factor the timeline into the thesis.
Treating the PRV as the whole investment thesis. The PRV is a cash infusion, not a cure. If the underlying drug fails commercially, the company still has to develop its pipeline. The PRV buys time; it doesn’t buy success. Our foundational investing guide covers how to weigh catalyst optionality against pipeline fundamentals.

Final checklist

Does the drug have a Rare Pediatric Disease designation on file with the FDA?
Is the PDUFA date before September 30, 2029 (the current sunset)?
Has the company publicly discussed PRV eligibility in investor materials?
What is the company’s market cap versus expected PRV sale price ($80-180M)?
Will the PRV sale proceeds fund the pipeline without a dilutive offering?
Are you positioned before the approval decision, not after the sale announcement?

Priority review vouchers are one of the few biotech catalysts where the math is publicly verifiable: the FDA publishes who gets a voucher, and the company discloses the sale price. Do the work before the market does. Start with our foundational investing guide if you’re new to biotech catalysts, then track the PRV-eligible PDUFA dates on the FDA calendar before each decision.